Laurent Levy, PhD
Chief Executive Officer
Laurent Levy is the co-founder of Nanobiotix and has served as Chief Executive Officer since March 2003. He was first appointed as Chairman of the Executive Board on May 27, 2004. Laurent has extensive experience in sciences and techniques related to nanotechnologies. His research at the frontier of biotechnology and nanotechnologies has resulted in the development of several concrete applications including Nanobiotix lead product candidate NBTXR3, which could expand therapeutic options and improve outcomes for patients with cancer.
Laurent's mission goes beyond simply curing major diseases like cancer. He and his team are on a mission to unlock humanity's limitless potential or, as they call it, to "Expand Life". From exploring the use of nanotechnology to increase processing power and reshape the brain, to resolving the issues of rapid therapeutic clearance to revolutionize the paradigm of how intravenously administered treatments are designed and delivered--and much more. Mr. Levy's true goal is to help inspire humanity to push beyond boundaries and discover a better way of life. Defeating cancer with the team at Nanobiotix and NBTXR3 is the first step, but only one of many on a bold journey.
From 2000 to 2003, prior to the founding of Nanobiotix, Laurent served as consultant for Altran Technologies and worked in the development of the application of nanotechnologies with companies such as Sanofi S.A., Guerbet S.A., and Rhodia S.A., as well as for early-stage biotechnology companies. He has served as President of the Supervisory Board of Valbiotis S.A. (Euronext Paris: ALVAL) since March 2017, was Vice Chairman of the Executive Board of the European Technology Platform on Nanomedicine (ETPN) from December 2012 to June 2019 and as a founding member of the Nanomedicine Translation Advisory Board (a division of ETPN) from June 2014 to June 2019.
Laurent has authored more than 35 international scientific publications and communications, has applied for and secured several patents, and regularly speaks on the topic of using nanoparticles to fight cancer and other diseases. He holds a Doctorate in Physical Chemistry, specializing in nanomaterials, from the Pierre and Marie Curie University (Université Paris VI Pierre et Marie Curie; UPVI-ESPCI) in Paris and from the CEA (Commissariat à l’Énergie Atomique et aux Énergies Alternatives), and a DEA (advanced studies and diplomas) in Physics of Condensed Matter from the UPVI-ESPCI. Laurent completed his studies with a post-doctoral fellowship at the Institute for Lasers, Photonics and Biophotonics at the State University of New York at Buffalo (SUNY Buffalo). Nanobiotix was created as a spinoff based on the findings from his post-doctoral thesis.
Leonard A. Farber, MD
Chief Clinical and Medical Affairs Officer
Leonard A. Farber, MD, brings extensive executive experience in developing and growing centers and departments within the oncology sector. Prior to joining Nanobiotix, Dr. Farber was chief medical officer and executive VP of clinical research at EHMET Health. He remains the senior clinical advisor for PreludeDx and serves as senior medical director and section chief of radiation oncology for the multi-specialty management system Care to Care. He is also the senior medical director of Anatom-e information system where he is involved with product development and integration of AR and VR into clinical practice.
Dr. Farber is a scientific advisory board member of Genomic Health, Adgero Biopharmaceuticals (acquired by Kintara Therapeutics in 2020), and the Global Pain Foundation/National Pain Foundation. He has also served as chief medical officer for the start-up Woodmont Pharmaceuticals, Inc.
Dr. Farber is a board-certified radiation oncologist who completed his residency in radiation oncology at the Hospital of the University of Pennsylvania where he served as chief resident. Prior to that he completed his internship at Beth Israel Medical center after graduating medical school from the Mount Sinai School of Medicine. He was the clinical director of radiation oncology at Long Island Radiation Therapy/Nassau Radiologic Group in New York and chairman of the Dept. of Radiation Oncology at Staten Island University Hospital of the North Shore University Hospital/LIJ Health System. In 2010, Dr. Farber became the founder and clinical director of The Farber Center for Radiation Oncology. In 2014, he sold the center to NY-Presbyterian Hospital, rebranding the center as the Lower Manhattan Cancer Center, and remained as the clinical director of radiation oncology. He followed this with a position of attending and professor of radiation oncology at Memorial Sloan Kettering Cancer Center in NY, City of Hope, and UCLA.
Bart Van Rhijn
Chief Financial Officer
Mr. Van Rhijn brings extensive experience in consultancy, technology, and life sciences industries and joins Nanobiotix after nearly 3 years as chief financial officer at Servier Pharmaceuticals, LLC (Servier US). Prior to Servier US, he held leadership roles in prominent organizations in Europe and North America, including PricewaterhouseCoopers, Philips and Galderma in Head of Tax, Senior Director of Mergers and Acquisitions, and Head of Finance positions. Mr. Van Rhijn’s track record reflects a relentless commitment to streamlining business operations, driving growth, and unlocking value. His varied experiences include the successful reorganization of a healthcare technology-enabled services business, coordination of strategic financing transactions, and the efficient scaling of commercial businesses. Mr. Van Rhijn has a strong commitment to organizational health and empowers his teams to embrace innovation, challenge the status quo, and drive optimal results while putting patients and customers first.
Mr. Van Rhijn received master’s degrees in Civil Law and Tax Law at Leiden University, The Netherlands, obtained his MBA with honors from Babson’s Olin School of Management, and his Certified Management Accountant (CMA) certification from the Institute of Management Accounts. In addition, Mr. Van Rhijn serves on the Advisory Board of a Boston-based healthcare start-up and is a venture partner at an emerging technology fund.
Chief People Officer
Anne-Juliette Hermant brings over 14 years in talent management and development acquired in different entities at AXA. She worked at AXA Partners for 3 years as Global Head of Talent, Development, Culture and Corporate Responsibility. Before AXA Partners, Anne-Juliette served as Chief Learning Officer of the AXA Group and was the Founder and Head of the AXA Research Fund, a €100 million fund created by the AXA Group to support frontier science in all fields related to an understanding of the risks faced by human society.
Anne-Juliette was born in Strasbourg, France and grew up between the French Caribbean islands of Guyane, Martinique and Guadeloupe. She relocated to Paris to pursue her studies and has remained in the city throughout her career.
Anne-Juliette studied French literature at the Ecole Normale Supérieure and Politics at Sciences Po Paris.
VP Strategy & Operational Excellence
Anne-Sophie Larivière is VP Strategy and Operational Excellence at Nanobiotix and brings over 10 years of experience both in strategic consulting and in the life science industry.
She started her career in Singapore at Sanofi. She then joined Bionest Partners, a strategic consulting boutique, where she focused on supporting US biotech companies plan their commercialization strategies in Europe. Her domain of expertise was in rare diseases. At Bionest, Anne-Sophie worked for large pharmaceutical clients, biotechs, medtechs, and investment funds.
In 2017, Anne-Sophie joined MedDay Pharmaceuticals, a French biotech company developing drug candidates in the field of neurodegenerative diseases. There, she held various roles, from Launch Project Manager to Strategic Marketing Director. At MedDay, Anne-Sophie worked cross-functionally and with a role of coordination, alignment and facilitation across all departments of the company. Her final role was as Value Strategy Director, responsible for external corporate communication and preparation of a possible transaction.
Anne-Sophie is an Engineer by background and graduated from ESCOM and ENSIC engineer schools. She also holds a Specialized Masters from ESCP-Europe.
Extended Executive Management
Patrick Tricoli, Pharm.D., MBA,
CEO of Nanobiotix Corp. & Global Head of Business Development (Nanobiotix)
Patrick Tricoli is CEO of Nanobiotix Corp., the Nanobiotix US affiliate in Cambridge (MA) and Global Head of Business Development of Nanobiotix, focused on building the Nanobiotix US presence while cultivating cross-industry relationships. Prior to Nanobiotix, Patrick was well known for his lead roles at Sanofi in Partnering and Innovation R&D, and subsequently Head of External Innovation Europe, spanning 15 years, Europe, Asia, and the US markets where he led multiple teams in developing strong international BD relationships, Corporate Development strategies, and collaborative R&D partnership.
Patrick also currently serves as a Foreign Trade Advisr New England for the French government since 2017. He holds a Pharm D, Master in Pharmacology and Pharmacokinetic and Executive MBA from ESCP Europe.
VP, Strategic Marketing and Corporate Communication
Brandon Owens is VP, Strategic Marketing and Corporate Communications at Nanobiotix. Hailing from the Washington, D.C. area, Brandon Owens is a career marketer and prior to Nanobiotix, was at Publicis New York on the Citigroup account. Brandon was responsible for Citi’s global reputation management communications and focused on integrated campaigns meant to influence policy decisions relevant to banking in over 100 different countries.
After studying business at the University of Maryland, Brandon began his career selling software for a small company in Baltimore, Maryland. He then moved to Chicago, Illinois to begin his career in advertising. Brandon moved to New York in 2013 and has since represented brands including Verizon, Diageo, and Citi.
Brandon will lean on his experience in the advertising industry to help deepen public understanding of Nanobiotix’s mission and how that mission leads to the company’s innovations.
VP, Strategic Partnership, Qualified Person
Then, he was member of the executive board of Movianto where he supervised the compliance of pharmaceutical operations. Before coming to Nanobiotix, he worked at SGS,Life Science Laboratory Services, for more than 6 years, firstly responsible for the French market for pharmaceutic laboratory and then Managing Director.
Ventzislav Vassilev, M.D.
VP, Global Head Safety Vigilance
Ventzislav Vassilev is the Vice President, Global Head of Safety at Nanobiotix and brings over 20 years of experience within the pharmaceutical industry. He joined Nanobiotix in September 2019, after creating and developing the Medical Safety Department of Galapagos N.V.
His career started at Servier HQ at diverse positions within the Clinical Operations cover the Eastern European countries. In 2006, he was pointed out as Regional Head of Clinical Development in Singapore, when he was in charge of the set up and development of all R&D activities of Servier in South, South-East and Pacific Asia. After 4 years as Head of Medical Affairs and Pharmacovigilance (EMEA) within the CRO industry, Ventzislav Joined Astellas as Global Head of CNS portfolio in their Pharmacovigilance Division in Leiden, Netherlands.
Ventzislav is graduated as Medical Doctor from the Medical University in Sofia, Bulgaria, completed with Postgraduate training in Toxicity of the drugs and Pharmacovigilance from University Paris 7 “Denis Diderot”, Hospital Lariboisière Saint-Louis, Paris, France.
VP, Global Head Clinical Operations
Peggy’s career has spanned several positions in the healthcare field, from hospital practice to large pharmaceutical to biotech industries.
As a Master’s Prepared Nurse, she had roles in hemodialysis, infection control and management of critical care units. Peggy took the opportunity to change her career when she and her family relocated. She joined the pharmaceutical industry with Roche, based in Lingolsheim, France, continued with Roche in US and moved to Sanofi prior to holding positions at 3 US biotech companies. In these companies, she held leadership positions in Clinical Development Operations, helping to bring new drugs through the regulatory approval process, while building and developing the department and its staff.
Her career has been fueled by her desire to help people, whether it be patients, their families or professional colleagues and staff.
SVP, Investor Relations
Kate McNeil has more than 20 years of experience in the life sciences industry, including communications and investor relations leadership for corporate and product brands, strategic financings and acquisitions, as well as clinical and regulatory developments in multiple therapeutic arenas for both public and private companies across development stages.
Most recently Kate served as a consultant, prior to which she served as the head of communications and investor relations for Invitae a leading medical genetics company. Before that, Kate served as executive director of investor relations for Amarin Corporation, a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, and as the primary external communications strategist for clinical, regulatory, and corporate developments for Cellectar Biosciences and Chelsea Therapeutics. These internal leadership roles followed various account management positions including assistant vice president at The Investor Relations Group (IRG), a communications consulting firm focused on providing investor and public relations guidance for micro and small cap companies in the healthcare, biotech and technology industries.
Gary M. Phillips, M.D.,
Chairman of supervisory board
Gary M. Phillips, M.D., has served as Chairman of the Supervisory Board since May 2021. With over two decades of experience in the pharmaceutical and healthcare industries, Dr. Phillips currently holds the position of President and CEO of OrphoMed. Prior, he was Executive Vice President and Chief Strategy Officer at Mallinckrodt Pharmaceuticals. Dr. Phillips has also served as Head of Global Health & Healthcare Industries at the World Economic Forum, President of Reckitt Benckiser Pharmaceuticals North America (now Indivior), and he held dual roles as President, U.S. Surgical and Pharmaceuticals and Global Head of Pharmaceuticals at Bausch & Lomb. Additionally, he has served in executive roles at Merck Serono, Novartis, and Wyeth. Dr. Phillips graduated Summa Cum Laude from the University of Pennsylvania, earning a B.A in biochemistry, holds an MBA from the Wharton School, and an M.D. with Alpha Omega Alpha distinction from the School of Medicine. He maintains an active medical license and practiced as a general medicine clinician/officer in the U.S. Navy, from which he was honorably discharged as a lieutenant commander.
Supervisory board member
Enno Spillner has served as a supervisory board member and chairman of the audit committee since 2014. He has more than 20 years of experience in the life science industry and currently serves as Chief Financial Officer and Member of the Management Board at German biotech company Evotec SE. From March 2013 until June 2016, he served as Chairman of the Management Board, Chief Executive Officer and Chief Financial Officer of 4SC AG. From September 2005 to March 2013 he acted as Chief Financial Officer of 4SC AG. Mr. Spillner started his life science industry career as Head of Finance and Managing Partner of the Munich-based biotech venture fund, BioM AG. He was also Managing Director of two portfolio companies, ACTIPAC Biosystems GmbH and Munich innovative Biomaterials GmbH. Prior to moving into the life science field, he was engaged in the media and marketing industry. Mr. Spillner earned his Dipl.-Kaufmann degree (master’s degree in business) at the University of Bamberg, Germany. Since December of 2019 he has also joined the Life Science Advisory Board of FCF Fox Corporate Finance.
Supervisory board member
Anne-Marie Graffin has served as a supervisory board member since 2013, as chairman of the appointments and compensation committee since 2017 and as Deputy Chairman of the supervisory board since July 2017. She has over 20 years of experience in life sciences and pharmaceutical companies. She has served as a non-executive board member of Valneva SE (Nantes, FR – Vienna, AT) since 2013 and of Sartorius Stedim Biotech SA (Aubagne, FR – Goëttingen, Ger) since 2015. After a varied career of over 20 years in the pharmaceutical industry, Ms. Graffin has expertise in both developing market access strategies and driving biotechnology companies’ growth. She has been a consultant to the pharmaceutical industry since 2011, developing many initiatives within the innovation and startups fields, connecting biotech and medtech startups with major EU venture capital firms and investors. Previously, she was a vice president at Sanofi Pasteur MSD, a European leader in the vaccine field, and acted as a member of the Executive Committee. Prior to working at Sanofi Pasteur MSD, she worked for five years at ROC as international brand manager. Ms. Graffin graduated from ESSEC Business School Paris.
Alain Herrera, M.D.
Supervisory board member
Dr. Alain Herrera, has served as a supervisory board member since 2013. Dr. Herrera has more than 25 years of experience in the pharmaceutical industry with a strong focus in oncology drug development and marketing. Dr. Herrera currently works at Alain Oncologie Consulting, an oncology consultancy company he started. In addition, Dr. Herrera currently serves as Head of Corporate Development, Managing Director of PharmaEngine Europe Sarl. Previously, Dr. Herrera served as head of the Oncology business at Sanofi-Aventis for 10 years. He also served as Vice President for the Global Oncology Business Strategy and Development from 2007-2008 and Head of the Global Oncology Franchise from 1998-2007. While at Sanofi-Aventis, he contributed to the worldwide registration of Oxaliplatin (Eloxatin®) and Rasburicase (Fasturtec®/Elitek®), as well as the Gastric and Head & Neck indications for Docetaxel (Taxotere®). Prior to Sanofi-Aventis, he served as Chairman of Chiron Therapeutics Europe, Managing Director at Pierre Fabre Oncology Laboratories and Head of the Oncology Platform at Roger Bellon (Rhône Poulenc). Dr. Herrera has also served as a Hematologist Consultant at Antoine Beclere Hospital since 1991.
Supervisory board observer
Christophe Douat serves as a supervisory board observer and is entitled, in this capacity, to attend all meetings of the supervisory board. Mr. Douat previously served as member of the supervisory board from 2011 until 2017 and from 2006 to 2009 when he was the lead investor. He is currently CEO of Medincell (MEDCL, Euronext), a pharmaceutical company that specializes in drug delivery technologies. Mr. Douat worked at the venture capital company Matignon Investissement & Gestion from 2001 to 2009, where he invested in a broad range of companies, and cofounded Matignon Technologies II, one of Europe’s largest funds specialized in medtech. Mr. Douat is also an alumnus of the Boston Consulting Group. He graduated from École des Mines de Paris, an engineering French “Grande Ecole” and holds an MS (US) and an MBA (Canada).